NO20073813L - Kladribinregime for behandling av multippel sklerose - Google Patents

Kladribinregime for behandling av multippel sklerose

Info

Publication number
NO20073813L
NO20073813L NO20073813A NO20073813A NO20073813L NO 20073813 L NO20073813 L NO 20073813L NO 20073813 A NO20073813 A NO 20073813A NO 20073813 A NO20073813 A NO 20073813A NO 20073813 L NO20073813 L NO 20073813L
Authority
NO
Norway
Prior art keywords
multiple sclerosis
treatment
cladribine
regimen
cladribine regimen
Prior art date
Application number
NO20073813A
Other languages
English (en)
Inventor
Giampiero De Luca
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073813(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Serono Lab filed Critical Serono Lab
Publication of NO20073813L publication Critical patent/NO20073813L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelsen angår bruken av kladribin for fremstilling av en farmasøytisk formulering for behandling av multippel sklerose, spesielt tilbakevendende-remitterende multippel sklerose eller tidlig sekundær progressiv multippel sklerose, hvor preparatet skal administreres oralt og hvor fornyede behandlinger er mulige.
NO20073813A 2004-12-22 2007-07-20 Kladribinregime for behandling av multippel sklerose NO20073813L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
NO20073813L true NO20073813L (no) 2007-09-21

Family

ID=36227798

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073813A NO20073813L (no) 2004-12-22 2007-07-20 Kladribinregime for behandling av multippel sklerose

Country Status (24)

Country Link
US (2) US7713947B2 (no)
EP (6) EP2275110B1 (no)
JP (7) JP5795456B2 (no)
KR (1) KR20070091662A (no)
AR (1) AR052830A1 (no)
AU (2) AU2005318190B2 (no)
BR (1) BRPI0517132B8 (no)
CA (2) CA3087419C (no)
CY (3) CY1112614T1 (no)
DK (2) DK2805723T3 (no)
EA (1) EA015799B1 (no)
ES (1) ES2921858T3 (no)
FR (1) FR18C1008I2 (no)
HR (1) HRP20120228T1 (no)
HU (2) HUE059133T2 (no)
IL (2) IL183930A0 (no)
LT (2) LT3332789T (no)
LU (1) LUC00064I2 (no)
MX (1) MX2007007610A (no)
NO (1) NO20073813L (no)
PL (3) PL1827461T3 (no)
SG (1) SG160391A1 (no)
SI (2) SI2805723T1 (no)
WO (1) WO2006067141A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649810A1 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
JP2021504363A (ja) 2017-11-24 2021-02-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 進行型多発性硬化症の処置における使用のためのクラドリビン処方計画
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
PL321431A1 (en) 1994-12-22 1997-12-08 Ortho Pharma Corp Soluble 2-chloro-2'deoxyadenosine compositions
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
US7572909B2 (en) 2002-09-25 2009-08-11 Brigham Young University Method for the preparation of 2-halo-2′-deoxyadenosine compounds from 2′-deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
CN1761471A (zh) * 2003-02-25 2006-04-19 应用研究系统Ars股份公司 利巴韦林与干扰素β在脱髓鞘疾病中的联用
EA009714B1 (ru) 2003-03-28 2008-02-28 Арес Трейдинг С.А. Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
RS20050735A (en) 2003-03-28 2008-06-05 Ares Trading S.A., Cladribine formulations for improved oral and transmucosal delivery
CA2649810A1 (en) * 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
CY2018006I2 (el) 2018-06-27
AU2011200768B2 (en) 2012-09-13
BRPI0517132B8 (pt) 2021-05-25
PL2805723T3 (pl) 2018-04-30
AU2011200768A1 (en) 2011-03-17
US20090081163A1 (en) 2009-03-26
JP6092945B2 (ja) 2017-03-08
CY1112614T1 (el) 2016-02-10
EP2275110A2 (en) 2011-01-19
ES2921858T3 (es) 2022-09-01
WO2006067141A1 (en) 2006-06-29
IL183930A0 (en) 2007-10-31
LUC00064I2 (no) 2018-03-28
LTPA2018503I1 (lt) 2018-03-12
EP2275110A3 (en) 2011-04-27
JP2015180685A (ja) 2015-10-15
HRP20120228T1 (hr) 2012-04-30
DK2805723T3 (da) 2018-01-29
US7713947B2 (en) 2010-05-11
BRPI0517132B1 (pt) 2020-02-18
JP5795456B2 (ja) 2015-10-14
EP2263678B1 (en) 2014-06-11
JP5908863B2 (ja) 2016-04-26
EA015799B1 (ru) 2011-12-30
US8377903B2 (en) 2013-02-19
JP6290962B2 (ja) 2018-03-07
JP6430554B2 (ja) 2018-11-28
US20100203017A1 (en) 2010-08-12
JP2008524313A (ja) 2008-07-10
SI3332789T1 (sl) 2022-08-31
EP1827461B1 (en) 2012-02-29
EP2805723B1 (en) 2018-01-17
CY1119790T1 (el) 2018-06-27
IL212421A (en) 2014-01-30
EA200701221A1 (ru) 2008-02-28
EP2805723A1 (en) 2014-11-26
JP2016138128A (ja) 2016-08-04
AU2005318190A1 (en) 2006-06-29
EP2263678A3 (en) 2011-04-27
AU2005318190B2 (en) 2010-11-25
LUC00064I1 (no) 2018-02-14
JP2013216664A (ja) 2013-10-24
CA2588966C (en) 2020-07-21
EP4070800A1 (en) 2022-10-12
CA3087419C (en) 2023-03-07
CY2018006I1 (el) 2018-06-27
SI2805723T1 (en) 2018-02-28
FR18C1008I2 (fr) 2019-03-01
CA3087419A1 (en) 2006-06-29
CA2588966A1 (en) 2006-06-29
MX2007007610A (es) 2007-08-03
KR20070091662A (ko) 2007-09-11
IL212421A0 (en) 2011-06-30
EP3332789B1 (en) 2022-04-06
JP2018165271A (ja) 2018-10-25
LT3332789T (lt) 2022-07-25
JP2017101061A (ja) 2017-06-08
DK3332789T3 (da) 2022-07-11
EP2275110B1 (en) 2013-07-10
EP2263678A2 (en) 2010-12-22
PL3332789T3 (pl) 2022-08-22
EP1827461A1 (en) 2007-09-05
LTC2805723I2 (lt) 2022-04-25
FR18C1008I1 (no) 2018-03-30
HUE059133T2 (hu) 2022-10-28
SG160391A1 (en) 2010-04-29
AR052830A1 (es) 2007-04-04
EP3332789A1 (en) 2018-06-13
JP2020193206A (ja) 2020-12-03
PL1827461T3 (pl) 2012-07-31
BRPI0517132A (pt) 2008-09-30
HUS1800009I1 (hu) 2018-05-02

Similar Documents

Publication Publication Date Title
NO20073813L (no) Kladribinregime for behandling av multippel sklerose
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
NO20043367L (no) Oralt farmasoytisk preparat
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201291089A1 (ru) Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций
EA201300420A1 (ru) Комбинации, которые содержат замещенный n-(2-ариламино) арилсульфонамид
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
JP2009505991A5 (no)
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
HUP0300709A2 (hu) Pemetrexedet monotioglikollal, L-ciszteinnel vagy tioglikolsavval együtt tartalmazó gyógyászati készítmény
SE0303480D0 (sv) Benzofuranes
BRPI0516545A (pt) uso de óleo de lavanda para a profilaxia e tratamento de neurastenia, distúrbios de somatização e outras doenças associadas ao estresse
JP2012097034A5 (no)
PT3332789T (pt) Regime de cladribina para o tratamento de esclerose múltipla
CL2009000965A1 (es) Tableta oral compuesta por un compuesto i que comprende un 10 a 20% en peso de la tableta o su sal farmaceuticamente aceptable, que comprende ademas de un agente aglutinante, un desintegrante, un diluyente; proceso de preparacion de la tableta; y su uso en el tratamiento de vih y enfermedades inflamatorias.
MX2009003930A (es) Novedoso cristal de (s)-(+)-2-(2-clorofenil)-2-hidroxi-etil carbamato.
GT200600244A (es) Inhibidores de la adenilato ciclasa soluble
JP2013531048A5 (no)
TR200605543A2 (tr) Sedef hastalığı için dana ödü-bira mayası formülasyonu

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application